- ►infekt.ch [PDF] - Free from Publisher P Aschner, MS Kipnes, JK Lunceford, M … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Sitagliptin 100 and 200 mg produced significant (P < 0.001)
placebo-subtracted reductions in A1C (−0.79 and −0.94%, respectively) and
fasting plasma glucose (−1.0 mmol/l [−17.1 mg/dl] and −1.2 mmol/l ... Cited by 194 - Related articles - BL Direct - All 13 versions
- ►januvia.se [PDF] - Free from Publisher B Charbonnel, A Karasik, J Liu, M Wu, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a
metformin dose titration/stabilization period, and a 2-week, single-blind,
placebo run-in period, 701 patients, aged 19–78 years, with mild to ... Cited by 202 - Related articles - BL Direct - All 9 versions
J Rosenstock, R Brazg, PJ Andryuk, K Lu, P … - Clinical therapeutics, 2006 - Elsevier This was a 24-week, multicenter, ran domized, double-blind, placebo-controlled,
parallel group study in patients aged ≥18 years (ClinicalTrials. gov
NCT00086502). At screening, all patients began a diet/exercise program that ... Cited by 162 - Related articles - All 4 versions
- ►januvia.se [PDF] I Raz, M Hanefeld, L Xu, C Caria, D Williams … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis The aim of this study was to assess the efficacy and
safety of sitagliptin (MK-0431) as mono- therapy in patients with type 2
diabetes mellitus and inadequate glycaemic control (HbA 1c Q7% and e10%) on ... Cited by 164 - Related articles - All 5 versions
MA Nauck, G Meininger, D Sheng, L Terranella … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 132 - Related articles - All 7 versions
R Scott, M Wu, M Sanchez, P Stein - International journal of clinical practice, 2007 - interscience.wiley.com The aim of this study was to assess the efficacy and tolerability of the
dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes
who have inadequate glycaemic control on diet and exercise. In a ... Cited by 98 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org E Bosi, RP Camisasca, C Collober, E … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The between-treatment difference (vildagliptin − placebo) in
adjusted mean change (AMΔ) ± SE in A1C from baseline to end point was −0.7
± 0.1% (P < 0.001) and −1.1 ± 0.1% (P < 0.001) in patients receiving 50 ... Cited by 147 - Related articles - BL Direct - All 10 versions
- Free from Publisher J Rosenstock, MA Baron, S Dejager, D Mills, … - Diabetes Care, 2007 - ncbi.nlm.nih.gov OBJECTIVE: To compare the efficacy and tolerability of vildagliptin and
rosiglitazone during a 24-week treatment in drug-naïve patients with type 2
diabetes. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, ... Cited by 142 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org BJ Goldstein, MN Feinglos, JK Lunceford, J … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind,
placebo-controlled, parallel-group study, 1,091 patients with type 2 diabetes
and A1C 7.5–11% were randomized to one of six daily treatments: ... Cited by 94 - Related articles - BL Direct - All 9 versions
FX Pi-Sunyer, A Schweizer, D Mills, S Dejager - Diabetes research and clinical practice, 2007 - Elsevier This 24-week, double-blind, randomized, multicenter, placebo-controlled,
parallel-group study performed in 354 drug-naïve patients with type 2 diabetes
(T2DM) assessed efficacy and tolerability of vildagliptin (50 mg qd, 50 mg ... Cited by 119 - Related articles - All 12 versions
